Sarah Elizabeth Muir

Dr. Sarah Elizabeth Muir

Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LBLucas Scott Blanton
Lucas Scott Blanton
Sarah Elizabeth MuirSarah Elizabeth Muir
Sarah Elizabeth Muir
NMNicole L Mendell
Nicole L Mendell
DWDavid Walker
David Walker
Introduction: Spotted fever group (SFG) rickettsioses are tick-transmitted infections caused by Gram-negative, obligately intracellular bacteria in the genus Rickettsia. They present as an acute undifferentiated febrile illness, and they are often accompanied by rash and/or eschar. Although the rash of SFG rickettsioses usually consists of macules and papules, some, like in Rickettsia parkeri rickettsiosis, can also manifest with papulovesicular or pustular lesions. Case: We herein present a case of SFG rickettsiosis, due to R. parkeri, that masqueraded as Sweet syndrome (the prototype neutrophilic dermatosis) after the initial results of a shave biopsy. Further investigation of the biopsy specimen by immunohistochemical and PCR analysis would eventually confirm SFG rickettsiosis, with R. parkeri being detected by real-time PCR. Discussion:Rickettsia parkeri is transmitted by the Gulf Coast tick (Amblyomma maculatum) and is an increasingly recognized cause of SFG rickettsiosis in the United States. Rickettsia parkeri should be considered in those with an acute undifferentiated febrile illness with lesions that are pustular or papulovesicular, as prompt recognition and empirical administration of doxycycline results in the rapid resolution of symptoms.

19 February 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
JKJoshua Klinnert
Joshua Klinnert
VOVasily Ovechko
Vasily Ovechko
MFMichelle Madden Felicella
Michelle Madden Felicella
AMApril Nicole McDougal
April Nicole McDougal
Sarah Elizabeth MuirSarah Elizabeth Muir
Sarah Elizabeth Muir
LBLucas Scott Blanton
Lucas Scott Blanton
Murine typhus (also called flea-borne or endemic typhus) is an undifferentiated febrile illness caused by the bacterium Rickettsia typhi. The disease, transmitted by rat and cat fleas, is endemic to seaboard regions worldwide. Recently, murine typhus has reemerged as an increasingly recognized cause of febrile illness in the United States, especially in Texas and Southern California. In addition to fever, manifestations often include headache, malaise, myalgias, and a maculopapular rash in approximately half of cases. Although usually considered a mild illness, when untreated, symptoms can last up to 3 weeks. Severe manifestations such as pneumonitis, acute kidney injury, and meningoencephalitis may occur. Historically, death has occurred in 0.4%, but in Southern California, the case fatality rate has been recently recorded at 1.8%. As murine typhus has reemerged, there have been growing reports that this infection has triggered hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory syndrome. We herein report two fatal cases of hemophagocytic lymphohistiocytosis secondary to murine typhus. Autopsy revealed typhus group rickettsial antigen in tissues via immunohistochemistry, along with hemophagocytosis. Interestingly, the classic vascular and perivascular histopathologic findings associated with disseminated rickettsial infection were absent. These findings highlight an aberrant inflammatory cascade leading to hemophagocytic lymphohistiocytosis.

8 April 2025 in Neurology
Verified
Journal Article
Closed access
NGNikolas Georgakis
Nikolas Georgakis
SMSakina Matcheswalla
Sakina Matcheswalla
Sarah Elizabeth MuirSarah Elizabeth Muir
Sarah Elizabeth Muir
JGJeffrey Griffin
Jeffrey Griffin
AVAbhishek Vyas
Abhishek Vyas
XLXiangping Li
Xiangping Li
To present a rare case of bilateral medial medullary infarction (MMI) mimicking Guillain-Barre syndrome (GBS) at the time of initial presentation due to ascending weakness. Bilateral MMI is a rare type of stroke typically presenting with flaccid or spastic quadriparesis, dysarthria, and hypoglossal nerve palsy. GBS can present with similar symptoms. Early recognition is crucial for timely management. NA. A 55-year-old male with a past medical history of hypertension, hyperlipidemia, diabetes mellitus, and coronary artery disease presented with rapidly progressive ascending weakness and numbness in all four extremities over two days. Exam showed asymmetrical flaccid quadriparesis (right more than left) with normal reflexes and impaired sensory modalities, mild dysarthria, and dysphagia. Given the ascending weakness, GBS was considered. Cerebrospinal fluid was unremarkable except for elevated protein (60 mg/dL). Magnetic resonance imaging subsequently showed bilateral MMI with a classic "airpod" or "heart" sign. CT angiogram of the head showed abrupt change in caliber of a proximally prominent right posterior inferior cerebellar artery with diffusely decreased caliber distally. Digital subtraction angiography did not reveal significant large vessel disease. The patient was treated with dual antiplatelet therapy. With physical therapy, his strength significantly improved over the two-week hospital course and he could ambulate with a rolling walker upon discharge. Bilateral MMI is very rare and can present with flaccid paralysis in the early phase, which can be mistaken for GBS. Physicians must maintain a high level of clinical suspicion for bilateral MMI in patients with initial symmetric flaccid weakness and recognize that lingual paresis is frequently absent in bilateral MMI. Patients must undergo thorough, repeated physical examinations for assessment of tone and deep tendon reflexes. Despite the common belief that bilateral MMI has a poor prognosis, our patient achieved a good outcome with significant improvement following supportive care. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Mr. Georgakis has nothing to disclose. Dr. Matcheswalla has nothing to disclose. Ms. Muir has nothing to disclose. Mr. Griffin has nothing to disclose. Mr. Vyas has nothing to disclose. Dr. Thatikonda has nothing to disclose. Dr. Li has nothing to disclose.

21 July 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
GPG. Parekh
G. Parekh
Sarah Elizabeth MuirSarah Elizabeth Muir
Sarah Elizabeth Muir
CPC.T. Park
C.T. Park
QSQ. Seigel
Q. Seigel

21 July 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Sarah Elizabeth MuirSarah Elizabeth Muir
Sarah Elizabeth Muir
RBR. Bui
R. Bui
AHA. Hansen
A. Hansen
AGA. Munoz Gozalez
A. Munoz Gozalez

1 January 2026 in Dermatology Research and Practice
Verified
Journal Article
Open access
Sarah Elizabeth MuirSarah Elizabeth Muir
Sarah Elizabeth Muir
SFShangyi Fu
Shangyi Fu
SKSarah Kesaria
Sarah Kesaria
JPJuan Pinto-Cuberos
Juan Pinto-Cuberos
AMAyezel Munoz-Gonzalez
Ayezel Munoz-Gonzalez
Background: Mycosis fungoides is the most common type of childhood‐onset primary cutaneous T‐cell lymphoma, and hypopigmented mycosis fungoides (hMF) is a rare, diversely presenting form of mycosis fungoides that is more common in young populations. Although phototherapy is the most used treatment for pediatric patients with hMF, there are currently no existing guidelines for dosing or duration of treatment. Methods: We performed a comprehensive narrative literature review on June 11th, 2024, utilizing the PubMed database of the current literature on the treatment of pediatric hMF with phototherapy. The search yielded 87 unique studies which were subsequently reviewed for relevancy. Twelve studies describing the results of phototherapy treatment for 285 pediatric patients were ultimately analyzed. Results: The median age range of patients was 5–18 years. Most patients presented with early‐stage disease (Stage IA or IB) characterized by hypopigmented patches and plaques, often located on the trunk and extremities. Narrowband ultraviolet B (NB‐UVB) therapy was the most common treatment modality. The majority of patients experienced complete or partial remission with phototherapy, with 61% of patients achieving complete remission and 31% of patients achieving partial remission with NB‐UVB, while 61% of patients achieved complete remission and 29% of patients achieved partial remission for PUVA. Relapse was common, with many patients requiring multiple treatment cycles. PUVA phototherapy had a higher relapse rate of 63%, compared to a 44% relapse rate for NB‐UVB phototherapy. The average cumulative dose was 60.31 J/cm 2 (53 cases) for NB‐UVB and 62.3 J/cm 2 (11 cases) for PUVA. The number of treatment sessions ranged from 17 to 146 sessions for NB‐UVB and from 21 to 258 sessions for PUVA. Adverse effects were reported in only one case, with most patients tolerating NB‐UVB well. Conclusion: This narrative review identified limitations with current reporting of phototherapy modalities, number and frequency of phototherapy dosing sessions, number of cycles of treatment, and cumulative dosages administered of phototherapy dosing in pediatric patients with hMF. Further research is warranted to better characterize phototherapy dosing for pediatric patients and improve the standardization of phototherapy treatment protocols.